Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

Moderna Inc. closed $129.71 short of its 52-week high ($170.47), which the company achieved on May 24th.

Igor Kirillov, head of Russia's nuclear and chemical defense, helped spread false claims about Ukraine, the U.S. and COVID-19 ...

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year ...

It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...

The document notes that a phase 1 trial of two experimental Moderna RSV vaccines in infants aged five to eight months was ...

Shares of Moderna Inc. MRNA inched 0.02% higher to $41.84 Monday, on what proved to be an all-around mixed trading session ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $41.83 which represents a decrease of $-0.99 or -2.31% from the prior close of $42.82. The stock opened at $42.24 and touched a low of $41.38 ...

Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on 23.

Moderna faces index removal, stock plunge, vaccine challenges, and lawsuits, while focusing on R&D in oncology and rare diseases for future growth.

Short interest for healthcare stocks in S&P 500 rose in November vs. October, while Moderna continued to be the most shorted ...

Palantir Technologies, MicroStrategy, and Axon Enterprise are set to join the Nasdaq 100 Index on Monday, Dec. 23, replacing ...